Central Research Institute (CRI) aims to develop promising peptide drugs for
treating neuroinflammatory diseases with special focus on Alzheimer’s disease,
the leading cause of dementia in old age.
Despite recent FDA-approved monoclonal antibody drugs, there still remain significant unmet needs for new therapeutic options with better efficacy
and improved safety. CRI is dedicated to discovering first-in-class peptide-based nanodrugs that prevent and treat AD. Following data demonstrate that ERDR1-derived KINE-peptide significantly reduces αβ burden in the brain of 5xFAD mouse model of Alzheimer’s disease and alleviates scopolamine-induced cognitive impairment as well.